Fresenius Hid 'Serious' Health Risks Of GranuFlo, Suit Says
By Sindhu Sundar (August 27, 2013, 2:14 PM EDT) -- Fresenius USA Inc. was hit with a false advertising suit in California state court Friday by a proposed class claiming the company knowingly concealed the health risks of its dialysis drug GranuFlo dry acid concentrate, including heart attack and stroke.
The plaintiffs, who claim they had received the drug in the course of dialysis treatment since 2000, accuse Fresenius of carrying out a scheme to promote the product despite knowing about its dangerous side effects, including cardiac arrhythmias and other heart ailments.
The company began selling GranuFlo in 2003, after gaining U.S. Food and Drug Administration approval, according to the complaint....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!